Abstract Background: Vasovagal syncope is the most common cause of syncope in children, and there is no satisfactory treatment currently. We evaluated the response to midodrine treatment in patients with vasovagal syncope who failed to benefit from conventional, non-pharmacologic treatments. Materials and methods: The study was a single-centre retrospective study. The data of 44 children between the ages of 6 and 18 years, who were diagnosed with recurrent vasovagal syncope, did not benefit from non- pharmacological treatments, and received midodrine treatment from 2015 to 2022 were enrolled in the study. Results: In total, 44 patients, 38 (86.4%) were girls, and 6 (13.6%) were boys. The primary outcome measure was the change in frequency of vasovagal syncope episodes from baseline to 6 months after treatment with midodrine. Patients received a midodrine treatment at an average of 2.5–5 mg/day and were followed for a median of 23.07 (8–72) months. The median number of syncope was 4.2 (3–9.8)/year prior to treatment and 1.2 (1–5)/year ( p = 0.01) following the treatment. There was a significant improvement in syncope episodes in all patients. Conclusion: Vasovagal syncope is the common cause of syncope in children, and its treatment has not yet been found satisfactory. Midodrine treatment was found to be effective and safe in paediatric patients with recurrent vasovagal syncope. However, further research is needed to determine the most effective treatment for this condition.
Basunlu et al. (Thu,) studied this question.